Junlian Medical Enterprise Development Update · Issue 7, 2025

Ribo Life Science Completes Series E Financing, Accelerating Global Strategic Layout of Small Nucleic Acid Drugs

Suzhou Ribo Life Science Co., Ltd. announced that it recently completed a new round of private equity financing exceeding 200 million RMB. The proceeds from this financing will primarily be used to accelerate the advancement of the company’s self-developed clinical pipelines in therapeutic areas such as cardiovascular, metabolic, renal, and liver diseases. Additionally, it will deepen the innovation and product development of its extrahepatic delivery technology platform and strengthen global R&D and industrial capacity building. Since its establishment, based on the high recognition and firm support of many well-known investors, the company has cumulatively completed multiple rounds of financing totaling over 1.8 billion RMB. From being one of the early pioneers in China's small nucleic acid field to becoming a global leader in siRNA therapy, Ribo Life Science has witnessed the vigorous development of small nucleic acid drug research and has accompanied and led the growth of China's siRNA industry. Currently, with a highly forward-looking global strategic layout, the company has established multiple R&D centers and a globally integrated small nucleic acid drug development system in Kunshan (Suzhou), Beijing, and Europe. Through independent innovation, Ribo has built a rich pipeline of siRNA drugs and achieved full lifecycle technical coverage for small nucleic acid drugs from early-stage research to commercialization.

The First China-Developed KRAS G12C Inhibitor - Innovent Bio's Dabot® Approved for Marketing in Macao

Recently, Dabot® (Fulzerasib Tablets), the first KRAS G12C inhibitor independently developed by a Chinese company, has officially been approved for marketing by the pharmaceutical regulatory authority of the Macao Special Administrative Region, China. It has become the first China-developed KRAS G12C inhibitor approved in Macao, bringing a new precision targeted treatment option for patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC) in Macao. The approval and launch of Dabot® in Macao marks another significant breakthrough for Innovent Bio's innovative drugs in the Greater China region. Innovative products such as Tyvyt® (Daboshu®), Byvasda® (Dayoutong®), Sintilimab (Xinbile®), and Pemazyre® (Dabotan®) have already been approved for marketing in Indonesia, Hong Kong, Macao, Taiwan, and other countries or regions. Additionally, several products are in the process of registration and application for marketing in Brazil, Mexico, Colombia, India, and other regions, with the potential to bring more innovative therapies to patients across Latin America and Southeast Asia.

Harbour BioMed and Kelun-Biotech Initiate Global Phase II POLARIS Clinical Trial for Long-Acting Fully Human TSLP-Targeted Antibody HBM9378/WIN378 in Asthma Treatment

Harbour BioMed (Stock Code: 02142.HK), a global biopharmaceutical company focused on the discovery and development of innovative antibody therapies in the fields of immunological diseases and oncology, recently announced that its partner, Windward Bio AG (hereinafter referred to as "Windward Bio"), has initiated the POLARIS clinical study—a randomized, double-blind, placebo-controlled global Phase II trial aimed at evaluating the dosing regimen, safety, and efficacy of HBM9378/WIN378 in asthma patients. Preliminary data is expected to be released by mid-2026. HBM9378/WIN378 is a potential best-in-class long-acting monoclonal antibody targeting thymic stromal lymphopoietin (TSLP). TSLP is a well-validated cytokine that plays a key role in the progression of various immunological diseases, including asthma and chronic obstructive pulmonary disease (COPD). HBM9378/WIN378 was initially co-developed by Harbour BioMed and Kelun-Biotech as an antibody drug (also known as SKB378), with both parties sharing global rights. Earlier this year, Harbour BioMed and Kelun-Biotech entered into a strategic collaboration with Windward Bio, granting the latter exclusive rights to research, develop, manufacture, and commercialize the antibody globally (excluding Greater China and certain Southeast Asian and West Asian countries).

Zhongsheng Suyuan Successfully Administers First Dose of iDAP Therapy for Early-Onset Parkinson's Disease

Recently, the "Clinical Trial to Evaluate the Safety, Tolerance, and Preliminary Efficacy of Allogeneic Dopaminergic Neuronal Progenitor Cell (iDAP) Injection for the Treatment of Parkinson's Disease," conducted by a top domestic neurology team in collaboration with Zhongsheng Suyuan, has achieved significant progress — the first early-onset Parkinson’s disease (EOPD) subject successfully completed dosing in June 2025! On the same day after surgery, the subject was able to get out of bed and converse freely without any adverse reactions. A CT scan seven days post-surgery showed no intracranial edema or bleeding, and the investigators judged all aspects to be in good condition, leading to a smooth discharge. The subject will continue to be observed for safety and efficacy indicators according to the clinical protocol. This dosing marks Zhongsheng Suyuan taking the lead in neuroregenerative therapy with a Chinese solution, breaking through the "young Parkinson's" dilemma, and igniting a beacon of hope for EOPD patients. NCR201 Injection, developed by Zhongsheng Suyuan Biotechnology Co., Ltd., is an induced pluripotent stem cell (iPSC)-derived dopaminergic neuronal progenitor cell (iDAP) therapeutic product with clear PET/CT imaging evidence showing significant new dopaminergic functional imaging signals in the transplant area. After six months of treatment with NCR201 Injection, multiple PD subjects have shown significant therapeutic effects.

Mablink Bioscience YL217 Project Completes First Subject Dosing

On July 2, 2025, Medilink Therapeutics (Suzhou) Co., Ltd. ("Medilink Therapeutics"), a clinical-stage biotechnology company, announced the successful first dosing of the first subject in the international multicenter Phase I clinical trial in China for its self-developed antibody-drug conjugate YL217. YL217 is an ADC drug targeting CDH17, developed based on Medilink Therapeutics' proprietary TMALIN® technology platform. YL217 is an antibody-drug conjugate targeting CDH17, primarily developed for gastrointestinal tumors. CDH17 is highly expressed in tumor tissues such as gastric cancer, colorectal cancer, pancreatic cancer, and hepatocellular carcinoma. Its target expression is associated with the metastatic progression of various cancers of gastrointestinal origin and is upregulated in advanced, well-differentiated tumors. YL217 was developed using Medilink Therapeutics' next-generation tumor microenvironment activatable novel toxin linker platform technology (TMALIN®), and the international multicenter Phase I clinical trial has been initiated.

Biosensors' Iberis RDN System Receives 5-Year Reimbursement Approval in France, Another Success in European Market Access

On July 15, Good News Again for the Market Access Progress of Bioheart's Pulnovo Iberis RDN System in Europe – France Officially Confirmed Granting the System a Five-Year National Health Insurance Qualification (with Eligibility for Renewal). This achievement not only represents high recognition of the clinical value of the Pulnovo Iberis RDN System but also marks further improvement in its clinical application support system in Europe. In the European market, the Pulnovo Iberis RDN System has gained recognition from multiple countries: Italy has included it in the recommended solutions for interventional treatment of hypertension; Germany, after rigorous technical evaluation, has incorporated the system into the clinical application sequence of mainstream medical centers; relevant guidelines in Spain have also listed it as a recommended technology, and commercialization is proceeding steadily. From clinical research to guideline recommendations, from technical access to commercial implementation, the Pulnovo Iberis RDN System is deeply penetrating the European hypertension treatment market with a dual-driven approach of "clinical value + compliant pathway." The Pulnovo Iberis RDN System, developed by Shanghai Antong Medical Technology Co., Ltd., a subsidiary of Shanghai Bioheart Biotechnology Co., Ltd. (02185.HK), is a multi-electrode renal artery radiofrequency ablation catheter system designed for interventional treatment of patients with resistant hypertension and drug-intolerant hypertension. RDN, this groundbreaking innovative procedure, has reached a significant milestone in the field of hypertension treatment, bringing new hope and treatment options to a wide range of hypertension patients.

Lingfu Bio Launches Fully Human Nanobody Rat Platform, Breaking Species Barriers to Empower New Drug Development

Lingfu Biotechnology Subsidiary Beijing Renyuan Xingsheng Biotechnology Co., Ltd. (referred to as "Renyuan Xingsheng") has officially released China’s first fully human nanobody rat (HuNanoRat), which is also the world’s second related platform. The launch of this breakthrough platform successfully crosses species barriers, opening a new pattern for the source innovation and R&D of nanobody drugs in China. Following the successful establishment of a fully human nanobody mouse, Renyuan Xingsheng, a subsidiary of Lingfu Biotechnology, once again achieved a major cross-species breakthrough by successfully developing China’s first fully human nanobody rat model based on the characteristics of the rat immune system. This milestone marks that China has entered a new stage of "running side-by-side" from "catching up" in the field of antibody drug discovery. The fully human nanobody rat platform of Renyuan Xingsheng provides a stable supply of rats, immunizing more rats with fewer antigens, and the developed antibody drugs have higher stability and specificity, providing a "Chinese solution" to help pharmaceutical companies break through technical bottlenecks and promote First-in-Class drug development. The company adopts an "authorized use + co-development" model to provide global pharmaceutical companies with one-stop solutions from antibody discovery to IND application. The first batch of cooperation projects have been launched, and in the future, the company will continue to expand in-depth cooperation with research institutions and pharmaceutical companies to jointly explore new fields in antibody drugs.

KingMed's Trusted Data Space Selected for National Pilot Program

On July 16, the National Data Administration announced the first batch of pilot projects for innovation and development in trusted data spaces. Guangzhou Kingmed Diagnostics Group Co., Ltd., a leading enterprise in the third-party medical testing industry, was successfully selected as the only private enterprise in the healthcare sector to receive this qualification, and also the only selected company in the third-party medical testing industry. This signifies that Kingmed Diagnostics' practices in secure circulation, value mining, and application of medical data have gained recognition at the national level, providing an innovative model to address challenges such as "reluctance and unwillingness to share" in industry data, especially medical data. A trusted data space is a data-sharing infrastructure based on consensus rules that connects multiple parties to achieve shared use of data resources. The trusted data space can be likened to a "data security house," where different data providers can place their data, enabling data sharing while ensuring full data security. With over 30 years of experience in the medical testing industry, Kingmed Diagnostics has built a robust medical testing ecosystem: it possesses core assets of more than 3 billion medical test data records, a service network covering over 90% of China’s population, serves more than 23,000 medical institutions, has established hundreds of disease collaboration networks at national, provincial, and regional levels, and organizes AI developer competitions in medical testing, successfully linking upstream and downstream players in the medical testing industry.

Innovent Bio and JD Health Sign Strategic Cooperation to Create a New Ecosystem of Full-Link Services in Weight Loss and Blood Sugar Reduction Fields

On July 14, Innovent Bio and JD Health officially signed a strategic cooperation agreement. The two parties will engage in in-depth cooperation in areas such as drug supply, omnichannel sales, and digital marketing, integrating their respective advantageous resources to provide consumers with diverse and high-quality medicines and health services. This strategic cooperation between Innovent Bio and JD Health covers areas such as supply chain collaboration, omnichannel sales, and digital marketing. In terms of supply chain collaboration, Innovent Bio, as a leading biopharmaceutical company in China, currently has 16 innovative drugs on the market, covering major disease areas such as oncology, autoimmune diseases, metabolism, and ophthalmology. Moving forward, the two parties will carry out customized supply chain collaborations based on the different characteristics of the drugs. In the field of omnichannel sales, JD Health, with its rich business formats, covers a diversified user base through online and offline JD Pharmacy and related medical institutions, meeting the needs of different users. Innovent Bio will collaborate with JD Health on corresponding omnichannel sales based on the characteristics of the drugs. In terms of digital marketing, Innovent Bio and JD Health will jointly conduct educational activities for weight loss and blood sugar reduction, including knowledge dissemination, information sharing, and medical education. The two parties will collaborate with industry experts and institutions to produce and release relevant content on weight loss and blood sugar control, and integrate multi-channel resources online and offline to disseminate health information to the public.

Lanxin Bio and Golden Age Health Sign Ten-Year Exclusive Strategic Cooperation for LX101

On July 14, Golden Age Health Pte. Ltd. ("GAH") and Innostellar Biotherapeutics Co., Ltd. ("Lanxin Bio") announced the signing of a ten-year exclusive Promotion Service Agreement. Under the agreement, GAH will gain exclusive rights to commercially promote Lanxin Bio's first-in-class (BIC) gene therapy candidate, LX101, in mainland China. LX101 is an adeno-associated virus (AAV) gene therapy designed to deliver a functional RPE65 gene to retinal cells to restore the visual cycle in patients with biallelic RPE65 mutation-induced inherited retinal dystrophy (IRD). It is currently undergoing Phase III clinical trial development in China, with key data expected to be released in the fourth quarter of 2025. Plans are underway to actively submit a New Drug Application (NDA) to the National Medical Products Administration (NMPA) of China. If approved, LX101 will provide eligible patients with a single-dose, long-lasting treatment aimed at halting or potentially reversing vision loss. GAH will leverage its comprehensive patient service platform, covering disease and medical education, market access, and patient support, to address unmet needs along the patient journey, such as disease awareness, timely diagnosis and treatment, and treatment accessibility and affordability. Through close collaboration, both parties aim to swiftly bring this life-changing therapy to patients in mainland China affected by RPE65 mutation-induced inherited retinal dystrophy, enabling them to "see a clearer future."

Recbio and India's Biological E Reach Product Licensing Collaboration on Recombinant Nine-Valent HPV Vaccine

Recently, Recbio (02179.HK) is pleased to announce that our company has partnered with Biological E, a renowned biologics company in India (hereinafter referred to as "BE Company").”）Recently, a product authorization cooperation agreement was signed for the recombinant nine-valent HPV vaccine REC603. Recbio will transfer vaccine formulation and sub-packaging technology to BE Company and, at an appropriate time, transfer bulk production technology. According to the agreement, BE Company is granted exclusive rights to develop, produce, and commercialize the recombinant nine-valent HPV vaccine in India and in tender markets led by UNICEF and PAHO. Currently, Recbio has received the upfront payment of the cooperation and will collect milestone payments based on the progress of the cooperation, as well as royalties based on a certain percentage of annual net sales. Founded in 1953, BE Company is the first private biologics company in India, with extensive experience in vaccine research, production, and commercialization. It is also an important partner of UNICEF and PAHO. This strategic cooperation with BE Company marks another significant milestone for Recbio in actively expanding into the Indian market and more international markets.

BioMap and Optoseeker Biotech Forge Strategic Partnership to Empower High-Throughput Single-Cell Screening with AI Large Models

BioMap, the Leader in AI Large Models for Life Sciences, and LightChaser Bio, an Innovator in Advanced Life Science Instruments, Announce Strategic Collaboration to Revolutionize Antibody Therapy Development

Kingmed Diagnostics' Liang Yaoming and Hisky's Shao Jinhua Awarded the Title of "Outstanding Builder of Socialism with Chinese Characteristics"

On July 29, the Sixth Commendation Conference for Outstanding Builders of Socialism with Chinese Characteristics among Non-public Economic Figures was held in Beijing. Wang Huning, member of the Standing Committee of the Political Bureau of the CPC Central Committee and Chairman of the National Committee of the Chinese People's Political Consultative Conference, attended and delivered a speech. Li Ganjie presided over the commendation conference, while Hao Mingjin, Chen Yiqin, and Gao Yunlong attended the event."Outstanding Builder of Socialism with Chinese Characteristics"Jointly selected by the United Front Work Department of the CPC Central Committee, the Ministry of Industry and Information Technology, the Ministry of Human Resources and Social Security, the State Administration for Market Regulation, and the All-China Federation of Industry and Commerce, this is a prestigious honor bestowed by the Party and the state upon non-public economic figures who are "patriotic, dedicated, law-abiding in operation, innovative in entrepreneurship, and committed to giving back to society." Liang Yaoming, Chairman and CEO of KingMed Diagnostics, Shao Jinlong, Chairman and General Manager of Hisky Medical, and 100 other non-public economic figures were recognized.Awarded"Outstanding Builder of Socialism with Chinese Characteristics" Title.

Legend Capital's Multiple Medical Portfolio Companies Honored in the "GEI China Unicorn Enterprise Research Report 2025"

On July 18, Great Wall Strategy Consulting released the "GEI China Unicorn Enterprise Research Report 2025." Medical companies invested in by Legend Capital—Abogen Biosciences, JINGFENG Medical, Poisedon Biotech, and CloudShip Biotech—were honored on the "2024 GEI China Unicorn Enterprise List." Data shows that in 2024, there were a total of 372 unicorn enterprises in China, with a combined valuation exceeding $1.2 trillion, averaging $3.34 billion per company. Among them, 11 super unicorn enterprises contributed over 40% of the total valuation, reaching $538.5 billion. Additionally, there were 53 newly minted unicorn enterprises, including three that became super unicorns.

Multiple Healthcare Portfolio Companies of Legend Capital Ranked on the '2025 9th Healthcare Investment Excellence List'

On July 30, 2025, Haoyue Capital officially released the "9th Healthcare Investment Excellence List," with Legend Capital and several of its invested healthcare enterprises honored on the list.

Best Innovative Pharmaceutical Company of the Year:

Anjiste Bio

Zhongsheng Traceability

Best Innovative Medical Device Company of the Year:

Boin Hearing

Dingkang Medical

Core Medical

Ligand Therapeutics

Tupai Medical

Stellar Sea Medical

Best Company in Annual Health Services and Smart Healthcare:

BioMap

Asian Healthcare

Best Biotech Company of the Year:

Borui Ce

Best Return on Investment Fund in Healthcare for the Year:

Legend Capital

Best Investment Institution for Annual Innovative Medical Devices:

Legend Capital

Best Biotech Investment Institution of the Year:

Legend Capital

Annual Healthcare Investor:

Tang Hong, Managing Director of Legend Capital

Young Investor in Medical Health of the Year:

Yang Shujun, Investment Director of Legend Capital

Stellar Sea Medical and Innovent Bio Awarded the Title of "Potential Unicorn Enterprises" in Shenzhen 2025

On July 18, the 2025 China (Shenzhen) Unicorn Enterprise Conference opened in Shenzhen, and the "Shenzhen Unicorn and Gazelle Enterprise Research Report 2025" was officially released.

Following the evaluation by the Shenzhen Gazelle Unicorn Enterprise Evaluation Committee, StarSea Medical was honored with the 2025 Shenzhen "Potential Unicorn Enterprise" award for its industry-leading advantages in technological innovation and application. Similarly, DeepBiogen received the same recognition for its breakthrough achievements in mRNA innovative therapies and LNP delivery technology. In this selection process, Shenzhen established a tiered evaluation standard with Shenzhen characteristics—ranging from unicorn to potential unicorn to seed unicorn. After preliminary data screening, field visits, valuation verification, re-screening, and review by the evaluation committee, a total of 42 unicorn enterprises, 149 potential unicorns, 143 seed unicorns, and 215 gazelle enterprises were selected. Among them, the 149 potential unicorn enterprises have a total valuation of nearly 350 billion yuan, with an average valuation of approximately 2.4 billion yuan.

Starsea Medical was founded in October 2020, with its headquarters located at Nantai Cloud Innovation Valley in Guangming District, Shenzhen. It is an innovative medical technology enterprise specializing in the 4E00 disposable endoscopic interventional diagnosis and treatment business, integrating research and development, production, sales, and service. The company’s product planning covers fields such as urology, ICU, gynecology, emergency medicine, and anesthesia. The founding team of Starsea Medical comes from leading domestic and international medical device companies, possessing over a decade of extensive experience in endoscopic product development, global marketing, and production management.

Deep Biologics, established in 2019, is committed to developing a world-leading LNP delivery technology platform and innovative RNA therapies to address unmet clinical needs. Deep Biologics has built a diversity-oriented LNP library containing more than 5,000 ionizable lipids, applicable to the development of various innovative therapies, including mRNA vaccines and drugs, in vivo gene editing therapies, and in vivo cell therapies. Based on its proprietary mRNA and LNP technology platforms, Deep Biologics has developed a robust pipeline in the fields of infectious disease vaccines, rare diseases, metabolic diseases, and tumor immunology. It has also established collaborations with multiple biopharmaceutical companies both domestically and internationally to explore the development potential of this technology across broader therapeutic areas.

BioMap's Rare Disease Treatment Enzyme Project Selected as One of the First AI Biomanufacturing Typical Cases by the Ministry of Industry and Information Technology

Recently, the Ministry of Industry and Information Technology officially announced the "List of Typical Application Cases of Artificial Intelligence in the Biomanufacturing Field (First Batch)." The project "Efficient AI Large Model-based Modification of Pharmaceutical Enzymes for Enzyme Replacement Therapy" by BioMap was successfully selected as a typical case, making it the only life sciences foundational large model enterprise to receive this national-level recognition. This selection, organized by the Ministry of Industry and Information Technology, involved a nationwide evaluation aimed at systematically reviewing the effectiveness of AI technologies in key aspects of biomanufacturing, identifying outstanding projects with promotability, technical advancement, and exemplary leadership value to promote high-quality integrated development of "AI + Manufacturing." As the only large model platform company on this list, BioMap's inclusion not only reflects the nation’s emphasis on novel bio-intelligent technologies but also marks the transition from concept validation to practical implementation and effectiveness testing in the "AI-enabled biomanufacturing" approach. Based on its cross-modal foundational large model xTrimo, BioMap has built an intelligent system tailored for vertical tasks such as enzyme engineering, forming a comprehensive set of reusable algorithm modules and process frameworks in protein design, function optimization, and sequence reconstruction. Supporting full-chain closed-loop design from molecular modeling, performance prediction to experimental validation, it exhibits high scalability and rapid transferability, becoming a pioneering demonstration in promoting the integration of AI and biomanufacturing, with strong replicability and industry-leading impact.

Changde Medical® Wins Double Awards at the 14th CFS Financial Summit, Showcasing Innovation Strength

From July 16 to 17, the 14th CFS Financial Summit and the 2025 New Quality Productivity Entrepreneurs Conference was held in Shanghai, with the theme "Navigating the Waves of Change, Building Economic Resilience Together." Shanghai Changde Medical Technology Co., Ltd. (hereinafter referred to as "Changde Medical®")”) With its forward-looking strategic layout, outstanding product innovation capabilities, and highly efficient commercial operations, it has won the "2025 Outstanding Medical Science and Technology Innovation Award."”Ms. Miao Zhenghua, Chairman and General Manager of the company, was honored as "2025 Healthcare Innovation Leader."”Title. Since its establishment in 2021, Changde Medical® has been committed to "Innovation, Pragmatism, Quality, and Efficiency."”With core values, it is committed to efficiently creating a complete solution for minimally invasive treatment of vascular diseases that is reliable and accessible. The company focuses on the treatment areas of lower extremity arterial stenosis interventional therapy, thrombus management, venous disease interventional therapy, and chronic disease management. To date, Changde Medical® has obtained 9 medical device registration certificates (including 4 Class III), with 3 products having completed pre-market clinical trial enrollment and entered the stage of submission for registration approval; the peripheral drug-eluting stent received approval from the National Medical Products Administration (NMPA) in March 2025, entering the special review process for innovative medical devices ("green channel"), and is currently in the clinical trial enrollment phase. Since the approval and market launch of multiple products such as the peripheral vascular constraint-type balloon dilation catheter, intermittent pulse pressure therapy device, thrombus aspiration system, handheld aspiration catheter kit, and peripheral coils, the company’s commercial promotion has been rapidly advancing. Meanwhile, Changde Medical® is accelerating its expansion into overseas markets, with several products having initiated CE certification applications. Among them, the peripheral vascular constraint-type balloon dilation catheter was the first to receive market approval from Brazil's National Health Surveillance Agency (ANVISA), marking substantial progress in internationalization.

BoYin Hearing Selected as a "Star of Industry-Education Integration" Enterprise in Sichuan Province

On July 22, 2025, the selection results of Sichuan Province's "Industry-Education Integration Star" enterprises were officially announced. Boyin Hearing Technology (Shanghai) Co., Ltd. was honored to be selected due to its outstanding performance and significant contributions in the field of industry-education integration! On March 22, 2024, Boyin Hearing Technology signed a strategic cooperation agreement with Sichuan Vocational College of Nursing, jointly establishing China's first hearing rehabilitation industry college — Boyin Hearing Rehabilitation Industry College. This collaboration focuses on building a hearing rehabilitation education system and technological innovation, laying a solid foundation for future talent cultivation. Meanwhile, we have also achieved key breakthroughs in cutting-edge technology exploration. On March 3, 2025, Boyin Hearing Technology reached a strategic cooperation with the School of Computer Science and Technology at East China Normal University to jointly establish the "AI Audio Interaction and Auditory Cognition Joint Laboratory." The inauguration ceremony of this laboratory was grandly held on June 10, 2025, at the Putuo Campus of East China Normal University. In the future, Boyin Hearing Technology will cherish this honor, continue to deepen its commitment to industry-education integration, increase investment, explore innovative cooperation models, further expand the depth and breadth of integration, provide higher-quality products and services for hearing-impaired patients, strengthen the talent foundation for industry development, and let the light of industry-education integration illuminate the path forward for the hearing health cause.